X-Message-Number: 4622
From: John de Rivaz <>
Newsgroups: sci.cryonics
Subject: Cryolife investment takes off
Date: Sat, 08 Jul 1995 11:01:22 GMT
Message-ID: <>
This is an investment I missed, but maybe when the excitement wears
off the price will come down again and it will be worth buying.
This is forwarded from misc.investment:
CRYL was mentioned last week in Dick Davis Digest. Price was 9 3/4 X
10 1/4 then. It really took off. Today it set another all time high
(17) for the third day in a row. Here's yesterday's story on Dow Jones:
7/6/95 =CryoLife At 2nd 52-Wk High; Co Cites Positive Press
Mention
By Jane J. Kim Dow Jones Staff Reporter
NEW YORK -DJ- CryoLife Inc. (CRYL) shares set a second
consecutive 52-week high after a bullish interview with an
analyst who follows the company appeared in today's Investor's
Business Daily. The paper interviewed Robinson-Humphrey Co.
analyst John R. Runningen, who said the company has ''carved out
a very unique market niche with extraordinary barriers to
entry.'' CryoLife is an Atlanta provider of ultracold storage
of human tissues for use in transplants. CryoLife Chief
Financial Officer Edwin Cordell said the June 26 issue of the
Dick Davis Digest, a Fort Lauderdale, Fla., publication, carried
a report by Robert Jubb of Tomorrow's Stocks, a Scottsdale,
Ariz., newsletter. In the Dick Davis Digest, Jubb said that
CryoLife ''is very attractive'' and that the stock could reach a
long-term climb to the 24 area, for a potential 129% gain.
Since the company's May presentation at the New York Society of
Security Analysts, ''More people are talking about CryoLife,''
Cordell said. Runningen told Dow Jones that the company's May
presentation during which officials explained their business
strategy and highlighted products in the research and
development pipleline brought the stock to the attention of
people on Wall Street. ''I think the market may attribute
higher value to the stock,'' Runningen said. Cordell said the
company is developing two projects: FibRx, a blood-based
bioadhesive used as an alternative to sutures and surgical
staples, and Bioglue, a stronger version of the bioadhesive.
''I think U.S. demand will be very substantial,'' said Morgan
Keegan & Co. analyst Joseph Millsap. He said he sees potential
revenue from CryoLife's wound sealant of about $250 million to
potentially $400 million in the United States and about $650
million or greater overseas. Millsap said that the company is
getting a more ''meaningful valuation'' and is attracting more
institutional investors. ''The company is terribly underowned,''
Millsap said. Cordell estimated that the company had less than
5% institutional ownership. PRODIGY(R) interactive personal
service Runningen said the company is on track to meet his
earnings estimates of 9 cents a share for the second quarter, 36
cents a share for 1995 and 44 cents for 1996. A year ago,
CryoLife posted net income of 6 cents a share for the second
quarter and 27 cents for the year. Nasdaq-listed CryoLife
gained 1 3/4, or 13%, to 15 1/4 on volume of 295,300 shares,
compared with average daily volume of 29,200. Earlier, the stock
set a 52-week high of 15 1/2, passing the high of 14 1/4 set
yesterday. (END) DOW JONES NEWS 07-06-95 3:08 PM
--
Sincerely, ****************************************
* Publisher of Longevity Report *
John de Rivaz * Fractal Report *
* details on request *
****************************************
**** What is the point of life if it ends in death? ****
Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=4622